Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction

• Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection
• ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential for quarterly dosing
• Arrowhead will host a webinar today, October 14, at 2:30 PM ET/11:30 am PT to review additional interim results

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer’s disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain. In healthy volunteers, subcutaneous administration of ARO-MAPT achieved deep and durable reductions in cerebrospinal fluid (CSF) total tau, with a mean reduction of up to 73% at Day 105 and a maximum reduction of 85%.